Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM7 | Q14831 | 9/20 | 0.50 |
| ▸ | GHSR | Q92847 | 4/20 | 0.40 |
| ▸ | OXTR | P30559 | 4/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.39 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | PYGL | P06737 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19200373 | 1.00 | GRM7 (0.50) | GRM7GHSROXTRCYP3A4AVPR2 | |
| SCHEMBL20678708 | 0.92 | GRM7 (0.50) | GRM7GHSROXTRCYP3A4AVPR2 | |
| SCHEMBL20678643 | 0.92 | GRM7 (0.50) | GRM7GHSROXTRCYP3A4AVPR2 | |
| SCHEMBL20678646 | 0.92 | GRM7 (0.50) | GRM7GHSROXTRCYP3A4AVPR2 | |
| SCHEMBL20678709 | 0.92 | GRM7 (0.50) | GRM7GHSROXTRCYP3A4AVPR2 | |
| SCHEMBL19200470 | 0.87 | GRM7 (0.46) | GRM7GHSROXTRCYP3A4AVPR2 | |
| SCHEMBL19200378 | 0.87 | GRM7 (0.46) | GRM7GHSROXTRCYP3A4AVPR2 | |
| SCHEMBL19200379 | 0.87 | GRM7 (0.46) | GRM7GHSROXTRCYP3A4AVPR2 | |
| SCHEMBL19183214 | 0.87 | GRM7 (0.55) | GRM7GHSROXTRCYP3A4AVPR2 | |
| SCHEMBL20678696 | 0.86 | GRM7 (0.47) | GRM7GHSROXTRCYP3A4AVPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190031599-A1 | INDANE DERIVATIVES AS MGLUR7 MODULATORS | TAKEDA CAMBRIDGE LIMITED (GB) | 2019-01-31 | — | — | US | claimed |
| US-20190031599-A1 | INDANE DERIVATIVES AS MGLUR7 MODULATORS | TAKEDA CAMBRIDGE LIMITED (GB) | 2019-01-31 | — | — | US | disclosed |
| US-20190031599-A1 | INDANE DERIVATIVES AS MGLUR7 MODULATORS | TAKEDA CAMBRIDGE LIMITED (GB) | 2019-01-31 | — | — | US | disclosed |
| WO-2017131221-A1 | INDANE DERIVATIVES AS MGLUR7 MODULATORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190031599-A1 | INDANE DERIVATIVES AS MGLUR7 MODULATORS | GRM7, GRIN2B, GRM1 | GRM7 1/4885GHSR 283/4885OXTR 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.